+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?

Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?

Inflammation and Allergy Drug Targets 10(4): 236-246

Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been studied extensively in terms of biology, pathophysiology, diagnostic and prognostic values. Lp-PLA2 is an enzyme produced in atherosclerotic plaque by inflammatory cells, linked to LDL, HDL and VLDL. The binding of Lp-PLA2 to a specific lipoprotein fraction renders it more atherogenic. Increasing evidence has demonstrated Lp-PLA2 as a novel "ideal" marker for CVD as of its high specificity for vascular inflammation and low biologic variability. Thus, determination of Lp-PLA2 in individuals may provide clinically relevant information about their future risk of CVD events. In addition, Lp-PLA2 has been considered as a therapeutic target, which has been acted upon indirectly (lipid lowering medications) and directly (Lp-PLA2 antagonists such as darapladib) in pharmacologic therapies. This review will provide an overview on biochemistry, biology, proatherogenic, proinflammatory and proapoptotic effects of Lp-PLA2. Clinical utility and its validity as an independent CVD biomarker as well as a diagnostic biomarker to be detected in the very early stages of atherosclerosis will be also discussed. Moreover, the role of Lp-PLA2 as a pharmacologic therapeutic target is another theme of this review.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 054139438

Download citation: RISBibTeXText

PMID: 21539512

Related references

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs 14(6): 671-679, 2005

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiology 5(2): 159-173, 2009

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7(5): 511-517, 2007

Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Texas Heart Institute Journal 37(1): 25-39, 2010

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 5(6):, 2016

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology 1(2): 121-125, 2001

The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis. Current Atherosclerosis Reports 13(2): 132-137, 2011

Lipoprotein Associated Phospholipase A2 Assessment of a new assay for potential use as a marker of cardiovascular risk. Clinical Chemistry 48(6 Suppl.): A105, 2002

Lipoprotein-associated phospholipase A 2 : a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidaemic children. Annals of Clinical Biochemistry 54(5): 539-547, 2017

Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?. Progress in Cardiovascular Nursing 24(4): 181-189, 2009

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. American Journal of Cardiology 101(12a): 41f-50f, 2008

Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiology in Review 17(5): 222-229, 2009

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Current Opinion in Cardiology 24(4): 358-363, 2009

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 209(2): 528-532, 2010

Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). Journal of Thrombosis and Haemostasis 7(1): 41-48, 2009